Result: KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer

*Title*:

*Author/editor-in-chief*:

*Publication*:

Freiburg : Universität, 2023

*Physical description scale*:

1 Online-Ressource

*Format*:

*eBook*

*Language*:

*eng*

*Notes*:

Future oncology. - 18, 37 (2022) , 4079-4087, ISSN: 1744-8301

*DOI*:

10.2217/fon-2022-0776

*Result*: KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer